<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="90">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01188174</url>
  </required_header>
  <id_info>
    <org_study_id>BRD 09/6-C</org_study_id>
    <nct_id>NCT01188174</nct_id>
  </id_info>
  <brief_title>Clofarabine/Ara-C Treatment Combined With Reduced-intensity Conditioning Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Primary Treatment Failure</brief_title>
  <acronym>setric</acronym>
  <official_title>Clofarabine/Ara-C Treatment Combined With Reduced-intensity Conditioning Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Primary Treatment Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <authority>France: Afssaps - French Health Products Safety Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present trial will establish a prospective sequential Allogeneic Stem Cell
      Transplantation (allo-SCT) treatment combining both salvage chemotherapy and Reduced
      Intensity Conditioning (RIC) for primary treatment failure Acute Myeloid Leukemia (AML), to
      which future innovative strategies can be compared.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Endpoint: To improve the 2 year overall survival in patients with primary treatment
      failure

      * Secondary Endpoints:

        -  Feasibility of early transplantation within a multicenter trial

        -  Leukemia-free survival (LFS) at 2 years from transplantation

        -  Leukemia Response rate at day +30, +90 and 6 months

        -  Cumulative incidence of relapse, death from leukemia, and non-relapse mortality (NRM)

        -  Incidence and severity of acute and chronic Graft-versus-Host disease

        -  Feasibility and safety of early discontinuation of immunosuppressive therapy
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</study_design>
  <primary_outcome>
    <measure>Evaluation of the survival rate at 2 years after transplantation</measure>
    <time_frame>at 2 years after transplantation</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>AML</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clofarabine</intervention_name>
    <description>The present protocol aims to test the strategy of an early Reduced Intensity Conditioning (RIC) allo-SCT; in combination with a sequential preparative regimen for allo-SCT (Clofarabine, Intermediate dose Ara-C chemotherapy, followed by RIC with Cyclophosphamide, IV Busulfan and ATG; and delayed prophylactic infusion of donor lymphocytes (DLI) will be able to improve the outcome of patients with primary treatment failure AML.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of AML in the status of primary induction failure (i.e.
             persistent leukemia after 2 courses of induction chemotherapy or persisting bone
             marrow hypoplasia fol-lowing induction chemotherapy +/-minimal residual disease)

          -  Age: 18-55 years

          -  Availability of an HLA identical family donor OR unrelated donor with matching in
             10/10 alleles (HLA-A, B, C, DRB1, DQB1) or maximum of 1 allele or antigen mismatch OR
             family donor with maximum 1 allele mismatch.

          -  Have adequate renal and hepatic functions as indicated by the following laboratory
             values:

          -  Serum creatinine ≤1.0 mg/dL; if serum creatinine &gt;1.0 mg/dL, then the estimated
             glomerular filtration rate (GFR) must be &gt;60 mL/min/1.73 m² as calculated by the
             Modification of Diet in Renal Disease equation where Predicted GFR (ml/min/1.73 m2)
             = 186 x (Serum Creatinine)-1.154 x (age in years)-0.023 x (0.742 if patient is
             female)

          -  Serum bilirubin ≤1.5 mg/dL × upper limit of normal (ULN)

          -  Aspartate transaminase (AST)/alanine transaminase (ALT) ≤2.5 × ULN

          -  Alkaline phosphatase ≤2.5 × ULN

        Exclusion Criteria:

          -  Documented chloroma

          -  Patients having AML M3

          -  Documented leukemic infiltration of CNS/cerebrospinal fluid

          -  Karnofsky performance score below &lt; 60%

          -  Acute or chronic heart failure

          -  HIV infection, chronic viral hepatitis

          -  Severe neurological or psychiatric disorders

          -  Any circumstances that preclude the use of the drugs used within the protocol

          -  Prior allogeneic or autologous stem cell transplantation

          -  &gt; 3 courses of prior chemotherapy

          -  Denied informed consent

          -  Pregnancy or denied of effective contraceptive method
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamad Mohty, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Nantes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohamad Mohty, PhD</last_name>
    <email>mohamad.mohty@chu-nantes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noel Milpied, phd</last_name>
    </contact>
    <investigator>
      <last_name>Noel Milpied, Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Caen</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reman, Phd</last_name>
      <email>reman-o@chu-caen.fr</email>
    </contact>
    <investigator>
      <last_name>Reman, phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ibrahim Yakoub-Agha, Phd</last_name>
      <email>i-yakoub-agha@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Ibrahim yakoub-agha, Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mauricette Michallet</last_name>
      <email>mauricette.michallet@chu-lyon.fr &lt;mauricette.michallet@chu-lyon.fr&gt;</email>
    </contact>
    <investigator>
      <last_name>Mauricette Michallet</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier Blaise, Phd</last_name>
      <email>blaised@marseille.fnclcc.fr</email>
    </contact>
    <investigator>
      <last_name>Didier Blaise, Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nantes University hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamad Mohty, phd</last_name>
      <email>mohamad.mohty@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Mohamad Mohty, phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrice Chevallier, Md</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Paris saint Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gerad Socié, Phd</last_name>
      <email>gerad.socie@sls.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Gerard Socié, Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin Bilger</last_name>
      <email>karin.bilger@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne , huynh</last_name>
      <email>huynh.a@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Anne Huynh, Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <lastchanged_date>August 26, 2011</lastchanged_date>
  <firstreceived_date>August 11, 2010</firstreceived_date>
  <responsible_party>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>primary induction failure</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clofarabine</mesh_term>
  </intervention_browse>
</clinical_study>
